More articles from Editorial
- Given the ENHANCE trial results, ezetimibe is still unproven
We should beware of explaining away results that do not match our expectations.
- How safe are erythropoiesis-stimulating agents?
The year 2007 was a rough one for these agents, and the story is far from over.
- Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen
Much has been learned, but "nephrogenic" is misleading: this fibrosing disorder is not caused by the kidneys.
- Prostate cancer: Too much dogma, not enough data
In our management of prostate cancer, dogma often outweighs real data. Well-designed, randomized clinical trials are the answer.
- Acute aortic syndromes: Time to talk of many things
Lewis Carroll’s poem of 1872 is a useful starting point for identifying issues resulting from confusion over the various acute aortic syndromes.
- Exposing the complexity of HDL
HDL is a heterogeneous population of particles, and we should not be surprised if these particles differ in their effect on the arterial wall.
- Implications of the Spine Patient Outcomes Research Trial in the clinical management of lumbar disk herniation
What information does the Spine Patient Outcomes Research Trial offer for patients with lumbar radiculopathy and for their clinicians?
- Perhaps it is time for a change in policy on lung cancer screening
It is time to think seriously about using computed tomography as a screening test for lung cancer. We should include members of society beyond the scientific community in making this decision.
- Mumps surveillance and prevention: Putting mumps back on our radar screen
After the mumps vaccine was introduced, the incidence of mumps fell by 99%. Many of the current generation of physicians have never seen this disease.